NovaBridge Biosciences
NBP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001778016
In the last 90 days, NovaBridge Biosciences insiders filed 0 open-market purchases and 4 sales; 49 institutions reported holding it in 13F filings for Q2 2026, worth $48.1M in total; HHLR Advisors (Hillhouse) is the only superinvestor holding it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by NovaBridge Biosciences insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 4 filings
- 3 insiders, $92.3K in total
- Insiders trading
- 3
- Net value
- −$92.3K
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for NovaBridge Biosciences, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Dennis Phillip Andrew | Chief Medical Officer | 173,427 | Sep 21, 2026 | 2 |
| Cao Sean Wuxiong | Chief Bus. Development Officer | 266,467 | Sep 11, 2026 | 4 |
| Xu Cong Claire | EVP, Clinical Development | 304,201 | Sep 1, 2026 | 3 |
| Lenz Robert A. | Director | 17,218 | Aug 25, 2026 | 1 |
| Hagler Mark Arnold | Chief Commercial Officer | 230,000 | Jul 10, 2026 | 2 |
| Lin Liwei Lorraine | General Counsel | – | Jul 10, 2026 | 1 |
| Gupta Srishti | Chief Executive Officer | – | Jul 8, 2026 | 1 |
| Fu Wei | Director | – | Jun 30, 2026 | 1 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Apr 28, 2026 (view filing) | Apr 24 | 4 days | Hagler Mark ArnoldSee Remarks | PPurchase | +230.0K | $2.51 | +$577.3K | New position230.0K after | |
| May 18, 2026 (view filing) | May 14 | 4 days | Cao Sean WuxiongSee Remarks | SSale | −21.4K | $1.99 | −$42.6K | −37.9%35.1K after | |
| Jun 2, 2026 (view filing) | Jun 1 | 1 day | Xu Cong ClaireSVP, Clinical Development | SSale | −3.49K | $3.94 | −$13.8K | −1.2%290.2K after | |
| Jun 22, 2026 (view filing) | Jun 18 | 4 days | Dennis Phillip AndrewChief Medical Officer | SSale | −8.49K | $0.66 | −$5.61K | −5.1%157.9K after | |
| Jul 7, 2026 (view filing)7:50 PM ET | Jul 6 | 1 day | Xu Cong ClaireSVP, Clinical Development | SSale | −4.49K | $0.89 | −$3.99K | −1.5%298.1K after | |
| Sep 1, 2026 (view filing)6:00 PM ET | Aug 31 | 1 day | Xu Cong ClaireEVP, Clinical Development | SSale | −3.28K | $0.79 | −$2.59K | −1.1%304.2K after | |
| Sep 11, 2026 (view filing)4:30 PM ET | Sep 9 | 2 days | Cao Sean WuxiongChief Bus. Development Officer | SSale | −108.0K | $0.74 | −$79.9K | −28.8%266.5K after | |
| Sep 21, 2026 (view filing)4:05 PM ET | Sep 18 | 3 days | Dennis Phillip AndrewChief Medical Officer | SSale | −8.21K | $0.71 | −$5.83K | −4.5%173.4K after |